Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
S
|
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
|
5.3B CNY |
Loading...
|
|
| ZA |
S
|
Sasol Ltd
JSE:SOL
|
109.9B ZAR |
Loading...
|
|
| DE |
|
Basf Se
XETRA:BAS
|
42.4B EUR |
Loading...
|
|
| CN |
|
Ningxia Baofeng Energy Group Co Ltd
SSE:600989
|
247.4B CNY |
Loading...
|
|
| IN |
|
Pidilite Industries Ltd
NSE:PIDILITIND
|
1.4T INR |
Loading...
|
|
| ZA |
O
|
Omnia Holdings Ltd
JSE:OMN
|
13.7B ZAR |
Loading...
|
|
| JP |
|
Showa Denko KK
TSE:4004
|
2T JPY |
Loading...
|
|
| JP |
R
|
Resonac Holdings Corp
XMUN:SWD
|
10.8B EUR |
Loading...
|
|
| IN |
|
SRF Ltd
NSE:SRF
|
742.8B INR |
Loading...
|
|
| JP |
|
Mitsubishi Chemical Holdings Corp
TSE:4188
|
1.3T JPY |
Loading...
|
|
| JP |
M
|
Mitsubishi Chemical Group Corp
F:M3C0
|
6.7B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Shandong Sinobioway Biomedicine Co Ltd
Glance View
In the bustling world of biotechnology, Shandong Sinobioway Biomedicine Co Ltd stands as a dynamic player, deeply embedded in the heart of China's burgeoning pharmaceutical and biotech sector. Founded with a vision to harness the power of biology for transformative impacts, the company has charted a remarkable journey rooted in innovation and robust research capabilities. Sinobioway primarily delves into the development and commercialization of biological products, focusing on vaccines, antibodies, and other biopharmaceuticals. By emphasizing advanced biotechnologies, the company creates life-enhancing solutions, addressing both common and complex health challenges. Its strategic approach involves a blend of cutting-edge research, partnerships with academic institutions, and collaborations with global pharmaceutical giants, paving the way for market-leading products. Revenue streams for Sinobioway are predominantly driven by its diverse product portfolio that caters to a wide array of medical needs. Through comprehensive R&D, they've effectively commandeered a niche within the preventive medicine sector, particularly with their vaccines, which are in high demand due to increasing health awareness and governmental health initiatives. Additionally, the company fortifies its financial foundation through licensing deals, tapping into global markets and establishing a significant presence internationally. By strategically optimizing production processes and deploying an efficient distribution network, Sinobioway ensures its biomedicine products reach various demographics, thereby anchoring its position in the bioscience industry while continually seeking growth and expansion opportunities beyond local confines.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Shandong Sinobioway Biomedicine Co Ltd is -108.4%, which is below its 3-year median of -70.2%.
Over the last 3 years, Shandong Sinobioway Biomedicine Co Ltd’s Operating Margin has decreased from -54.5% to -108.4%. During this period, it reached a low of -114.6% on Jun 30, 2025 and a high of -25% on Dec 31, 2024.